TFA Therapeutics (RAJAF) Receivables (2020 - 2025)

TFA Therapeutics has reported Receivables for 6 years, with the latest figure at $100335.0 in Q4 2025.

• On a quarterly basis, Receivables rose 73.56% year-over-year to $100335.0 in Q4 2025; TTM through Dec 2025 was $100335.0, a 73.56% increase from a year earlier, with the FY2025 full-year figure at $100335.0, up 72.65% from the prior year.
• Receivables was $100335.0 for Q4 2025 at TFA Therapeutics, up from $57810.0 in the prior quarter.
• The five-year high for Receivables was $347554.0 in Q4 2021, with the low at -$7035.0 in Q4 2023.
• Average Receivables over 5 years is $89847.0, with a median of $44363.0 recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Receivables sank 174.04% in 2023, then surged 921.75% in 2024.
• Over 5 years, Receivables stood at $347554.0 in 2021, then slumped by 97.27% to $9502.0 in 2022, then sank by 174.04% to -$7035.0 in 2023, then soared by 921.75% to $57810.0 in 2024, then jumped by 73.56% to $100335.0 in 2025.
• The last three Receivables figures came in at $100335.0 (Q4 2025), $57810.0 (Q4 2024), and -$7035.0 (Q4 2023), per Business Quant data.